Monitor for any litigation filings or IBS exercise of reserved remedies (deposit account control, receivable direction, equity foreclosure). The company's ability to obtain alternative financing or settle the dispute will be critical to avoiding a liquidity crisis.
Price Chart
Executive Summary
Dalrada Technology Group disclosed the termination of financing agreements with IBS entities after no funding was ever provided. IBS has declared events of default and demanded approximately $1.16 million in fees, penalties, and other charges, which the company disputes. The dispute could materially impact liquidity and operations if IBS prevails or exercises reserved remedies.
Key Facts
- Genefic, a wholly owned subsidiary, terminated financing agreements with IBS on September 14, 2026; IBS responded by declaring events of default on September 15, 2026.
- IBS never provided any funding under the agreements — no loans, advances, or credit proceeds were received.
- IBS asserts total amounts due of $1,162,246, including a $126,430 note balance, $225,000 warrant redemption, $200,000 MGA termination fee, and $100,000 MCSPA termination fee.
- IBS has demanded additional collateral of at least $875,000 and reserved remedies including control over deposit accounts, direct receivable collection, and foreclosure on pledged equity.
- The company disputes all asserted defaults and amounts, and intends to vigorously defend against IBS's claims.
- The dispute could trigger cross-defaults on other indebtedness of the company or its subsidiaries.
Financial Impact
IBS demands total of $1,162,246 plus additional unquantified interest, ledger losses, and costs; collateral demand of $875,000; potential material adverse effect on liquidity and operations if IBS prevails.
Risk Factors
- IBS may pursue foreclosure on pledged equity interests, potentially affecting control of Genefic.
- Cross-default provisions could accelerate other indebtedness.
- Personal guaranty by CEO Brian Bonar creates additional pressure for settlement or defense costs.
- The company's dispute position may be challenged if IBS produces evidence of servicing defaults or ledger losses.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007291 |
| Document: 0001683168-26-007291-index-headers.html | 0001683168-26-007291 |
| Document: 0001683168-26-007291-index.html | 0001683168-26-007291 |
| Document: 0001683168-26-007291.txt | 0001683168-26-007291 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 8-K | $0.009000 $0.0150 | ▲ +66.67% | ▲ +67.65% | $0.0150 (+66.67%) |
Sep 22, 2026 4w ago | 8-K | $0.009000 $0.009000 | · 0.00% | ▼ −0.67% | $0.0150 (−66.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers